Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. DOI:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• Quint JK, O’Leary C, Venerus A, et al. Prescribing pathways to triple therapy: a Multi-Country, retrospective observational study of adult patients with chronic obstructive pulmonary disease. Pulm Ther. 2020;6(2):333–350. DOI:10.1007/s41030-020-00132-7
   PubMedGoogle Scholar
• Rodriguez-Roisin R, Rabe KF, Vestbo J, et al. Global initiative for chronic obstructive lung disease (GOLD) 20th anniversary: a brief history of time. Eur Respir J. 2017;50(1):1700671. DOI:10.1183/13993003.00671-2017
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. DOI:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced All-Cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, Double-Blind, multicenter, Parallel-Group study. Am J Respir Crit Care Med. 2021;203(5):553–564. DOI:10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32(7):1320–1328. DOI:10.1016/j.clinthera.2010.06.022
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. DOI:10.1136/thoraxjnl-2012-202872
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273(6):584–594. DOI:10.1111/joim.12067
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306. DOI:10.1136/bmj.f3306
   PubMed Web of Science ®Google Scholar
• Chang TY, Chien JY, Wu CH, et al. Comparative safety and effectiveness of inhaled corticosteroid and long-acting β(2)-agonist combinations in patients with COPD. Chest. 2020;157(5):1117–1129. DOI:10.1016/j.chest.2019.12.006
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparing initial LABA-ICS inhalers in COPD: real-world effectiveness and safety. Respir Med. 2021;189:106645.
   PubMed Web of Science ®Google Scholar
• Roberts M, Mapel D, Petersen H, et al. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769–776. DOI:10.3111/13696998.2011.622817
   PubMedGoogle Scholar
• Kern DM, Davis J, Williams SA, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res. 2015;16(1):52. DOI:10.1186/s12931-015-0210-x
   PubMedGoogle Scholar
• Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5(9):747–759. DOI:10.1016/S2213-2600(17)30217-5
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World evidence — what is it and what can it tell Us? N Engl J Med. 2016;375(23):2293–2297. DOI:10.1056/NEJMsb1609216
   PubMed Web of Science ®Google Scholar
• Frieden TR. Evidence for health decision making — beyond randomized, controlled trials. N Engl J Med. 2017;377(5):465–475. DOI:10.1056/NEJMra1614394
   PubMed Web of Science ®Google Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: clinical practice research datalink (CPRD) aurum. Inter J Epidemiol. 2019;48(6):1740–1740g. DOI:10.1093/ije/dyz034
   PubMed Web of Science ®Google Scholar
• Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14. DOI:10.1111/j.1365-2125.2009.03537.x
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. DOI:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• Quint JK, Mullerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the clinical practice research datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. DOI:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771–782. DOI:10.2147/CLEP.S117867
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. DOI:10.1016/S2213-2600(18)30368-0
   PubMed Web of Science ®Google Scholar
• Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1–6. DOI:10.1002/pds.3334
   PubMed Web of Science ®Google Scholar
• Suissa S, Moodie EE, Dell’Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459–468. DOI:10.1002/pds.4107
   PubMed Web of Science ®Google Scholar
• Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657. DOI:10.1136/bmj.l5657
   PubMed Web of Science ®Google Scholar
• Meropol SB, Metlay JP. Accuracy of pneumonia hospital admissions in a primary care electronic medical record database. Pharmacoepidemiol Drug Saf. 2012;21(6):659–665. DOI:10.1002/pds.3207
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in Real-World clinical practice. CHEST. 2019;155(6):1158–1165. DOI:10.1016/j.chest.2019.03.005
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of initial LAMA versus LABA in COPD: real-world cohort study. COPD. 2021;18(1):1–8. DOI:10.1080/15412555.2021.1877649
   PubMedGoogle Scholar
• Rothnie KJ, Chandan JS, Goss HG, et al. Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care. Int J Chron Obstruct Pulmon Dis. 2017;12:1663–1668. DOI:10.2147/COPD.S133891
   PubMed Web of Science ®Google Scholar
• Quanjer PH, ERS Global Lung Function Initiative, Stanojevic S, Cole TJ, Baur X. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. DOI:10.1183/09031936.00080312
   PubMed Web of Science ®Google Scholar
• Rebordosa C, Plana E, Aguado J, et al. GOLD assessment of COPD severity in the clinical practice research datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019;28(2):126–133. DOI:10.1002/pds.4448
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLOS One. 2016;11(3):e0151357. DOI:10.1371/journal.pone.0151357
   PubMed Web of Science ®Google Scholar
• Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018;378(18):1723–1724. DOI:10.1056/NEJMe1716802
   PubMed Web of Science ®Google Scholar
• Suissa S, Ariel A. Triple therapy in COPD: only for the right patient. Eur Respir J. 2019;53(4):1900394. DOI:10.1183/13993003.00394-2019
   PubMedGoogle Scholar
• Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med. 2021;9(7):684–685.
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease (2019 Report). http://goldcopd.org/gold-2019-global-strategy-diagnosis-management-prevention-copd/. 2019.
   Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. CHEST. 2020;157(4):846–855. DOI:10.1016/j.chest.2019.11.007
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on ­mortality. COPD. 2021:1–9. DOI:10.1080/15412555.2021.1977789. [Epub ahead of print].
   Google Scholar
• Ernst P. Blood eosinophils in COPD and the future risk of pneumonia. Eur Respir J. 2018;52(1):1800981. DOI:10.1183/13993003.00981-2018
   PubMed Web of Science ®Google Scholar
• Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–920. DOI:10.1093/aje/kwg231
   PubMed Web of Science ®Google Scholar